Because patients with muco-obstructive diseases (e.g., CF, COPD) commonly experience inappetence, and in the case of CF patients, nutrient malabsorption (92, 93), GLP-1 analogs may adversely impact the health status of these patients. This evidence concerns the gene GCG and cystic fibrosis.